Trial Profile
A Single Centre Two Part Randomized Phase I Study to Assess the Pharmacokinetics of an ER Formulation of AZD2516 and to Assess the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Ascending Doses in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Feb 2016
Price :
$35
*
At a glance
- Drugs AZD 2516 (Primary)
- Indications Gastro-oesophageal reflux; Neuropathic pain
- Focus Adverse reactions
- Sponsors AstraZeneca
- 07 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Feb 2011 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 13 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.